title: Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium.
abstract: We compared ciprofloxacin, rifampin, and gentamicin treatments, alone and in combination, for 5 days in the therapy of experimental aortic valve endocarditis in rats caused by a clinical isolate of vancomycin-resistant Enterococcus faecium. The MICs and MBCs of vancomycin, ciprofloxacin, rifampin, and gentamicin were 250 and > 1,000, 3.1 and 6.3, 0.098 and 1.6, and 12.5 and > 50 micrograms/ml, respectively. Infected rats were sacrificed after completing 5 days of therapy. Additional rats within each treatment group were followed for 5 days beyond the last dose of antibiotic therapy. Although survivals in the different groups were not significantly different after 5 days of therapy, survival was significantly better 5 days beyond the last dose of antibiotic therapy in rats treated with rifampin-containing regimens. The combination of ciprofloxacin and gentamicin was bactericidal in vitro and in vegetations from rats with enterococcal endocarditis. Rifampin alone was similarly bactericidal in vivo, but it was not significantly better than rifampin in combination with other antibiotics. Subpopulations resistant to rifampin, but not ciprofloxacin, were detected in the inoculum and in most vegetations during therapy. However, the combination of ciprofloxacin plus both gentamicin and rifampin reduced both the rifampin-susceptible and -resistant population in vegetations of 9 of 10 animals below the level of detection after 5 days of therapy. Nevertheless, a residual enterococcal population apparently remained in numbers of < 2 log10 CFU/g after 5 days of therapy, which resulted in relapse. Perhaps a longer course of therapy would have eliminated this residual population and improved efficacy.
authors.affiliation: Medical College of Pennsylvania, Philadelphia 19129.
authors.forename: M S
authors.initials: MS
authors.lastname: Whitman
authors.forename: P G
authors.initials: PG
authors.lastname: Pitsakis
authors.forename: A
authors.initials: A
authors.lastname: Zausner
authors.forename: L L
authors.initials: LL
authors.lastname: Livornese
authors.forename: A J
authors.initials: AJ
authors.lastname: Osborne
authors.forename: C C
authors.initials: CC
authors.lastname: Johnson
authors.forename: M E
authors.initials: ME
authors.lastname: Levison
mesh_terms: D000668:Ampicillin Resistance; D000818:Animals; D002939:Ciprofloxacin / Q000097:blood / Q000494:pharmacology*; D004195:Disease Models, Animal; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology*; D013293:Enterococcus faecalis / Q000187:drug effects / Q000502:physiology; D005839:Gentamicins / Q000097:blood / Q000494:pharmacology*; D016908:Gram-Positive Bacterial Infections; D008297:Male; D008826:Microbial Sensitivity Tests; D051381:Rats; D017207:Rats, Sprague-Dawley; D012293:Rifampin / Q000097:blood / Q000494:pharmacology*; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D005839:Gentamicins; D002939:Ciprofloxacin; D014640:Vancomycin; D012293:Rifampin